Reactions 1376 - 5 Nov 2011

Antineoplastics

Skin toxicity and peripheral neuropathy: casereport

A 59-year-old man developed skin toxicity and peripheralneuropathy during combination chemotherapy formetastatic colorectal cancer.

Following a diagnosis of advanced sigmoid colon cancerwith multiple liver metastases, the man began receivingmodified FOLFOX6 (fluorouracil, folinic acid [leucovorin]and oxaliplatin) with cetuximab. IV cetuximab 400 mg/m2

was infused over 120 min on day 1, with subsequentweekly doses of 250 mg/m2 infused over 60 min, andmFOLFOX6 was administered biweekly, with a reduceddose of oxaliplatin (60 mg/m2) and infusional fluorouracil(1650 mg/m2). He was discharged after 2 cycles, andsubsequently received cetuximab 500 mg/m2 withbiweekly mFOLFOX6 on an outpatient basis. After thefourth cycle, the doses of oxaliplatin and fluorouracil wereincreased to standard doses. After 6 cycles, he developedgrade 2 peripheral neuropathy and grade 2 skin toxicity.

Oxaliplatin was discontinued due to peripheralneuropathy. The man continued to receive outpatientchemotherapy, with no apparent regrowth of livermetastases.Mizota A, et al. FOLFOX plus cetuximab for a patient with metastatic colorectalcancer with icterus due to multiple liver metastases. Gan to Kagaku Ryoho 38:1205-1208, No. 7, 6 Jul 2011 - Japan 803062208

1

Reactions 5 Nov 2011 No. 13760114-9954/10/1376-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved